Endocyte (Endocyte) Total Assets : $355.20 Mil (As of Sep. 2018)

View and export this data going back to 2011. Start your Free Trial

What is Endocyte Total Assets?

Endocyte's Total Assets for the quarter that ended in Sep. 2018 was $355.20 Mil.

Total Assets is connected with ROA %. Endocyte's annualized ROA % for the quarter that ended in Sep. 2018 was -19.13%. Total Assets is also linked to Revenue through Asset Turnover. Endocyte's Asset Turnover for the quarter that ended in Sep. 2018 was 0.00.

Endocyte Total Assets Historical Data

The historical data trend for Endocyte's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endocyte Total Assets Chart

Endocyte Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Total Assets

Get a 7-Day Free Trial

162.86

212.80

178.39

143.49

100.76

Endocyte Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Total Assets	Get a 7-Day Free Trial															106.85	100.76	176.68	172.17	355.20

Endocyte Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Endocyte's Total Assets for the fiscal year that ended in Dec. 2017 is calculated as

Total Assets	=	Total Equity (A: Dec. 2017 )	+	Total Liabilities (A: Dec. 2017 )
	=	95.484	+	5.278
	=	100.76

Endocyte's Total Assets for the quarter that ended in Sep. 2018 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2018 )	+	Total Liabilities (Q: Sep. 2018 )
	=	347.197	+	8.008
	=	355.21

Endocyte (NAS:ECYT) Total Assets Explanation

Total Assets is connected with ROA %.

Endocyte's annualized ROA % for the quarter that ended in Sep. 2018 is

ROA %	=	Net Income (Q: Sep. 2018 )	/	( (Total Assets (Q: Jun. 2018 )	+	Total Assets (Q: Sep. 2018 ))	/ count )
	=	-50.432	/	( (172.169	+	355.204)	/ 2 )
	=	-50.432	/	263.6865
	=	-19.13 %

Note: The Net Income data used here is four times the quarterly (Sep. 2018) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Endocyte's Asset Turnover for the quarter that ended in Sep. 2018 is

	Asset Turnover
=	Revenue (Q: Sep. 2018 )	/	( (Total Assets (Q: Jun. 2018 )	+	Total Assets (Q: Sep. 2018 ))	/ count )
=	0.086	/	( (172.169	+	355.204)	/ 2 )
=	0.086	/	263.6865
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Endocyte Total Assets Related Terms

Thank you for viewing the detailed overview of Endocyte's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Endocyte (Endocyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endocyte Inc (NAS:ECYT) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.endocyte.com

Endocyte Inc is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases using precision medicine. Precision medicine is a medical discipline seeking to treat diseased cells with minimal impact on healthy cells. The company uses its proprietary technology to create novel small-molecule drug conjugates and companion imaging agents. The company's therapeutic areas are non-small cell lung, breast, colorectal, kidney, endometrial, prostate, and ovarian cancers; solid tumors; polycystic kidney disease; and inflammation.

Executives

Patrick Machado	director	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
John C Aplin	director	ONE AMERICAN SQUARE STE 2850, INDIANAPOLIS IN 46282
David R. Mcavoy	officer: General Counsel	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Alison A. Armour	officer: Chief Medical Officer	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Marc D Kozin	director
Michael T. Andriole	officer: Chief Financial Officer	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Lesley Russell	director	41 MOORES RD., FRAZER PA 19355
Beth Taylor	officer: VP Finance & Chief Acctg Off	3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Michael A. Sherman	director, officer: President and CEO	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fred A Middleton	director	400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Peter D Meldrum	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Ann Hanham	director	ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Chandra D Lovejoy	officer: VP of Regulatory Affairs	C/O PRONAI THERAPEUTICS, INC. 2150 - 885 WEST GEORGIA ST VANCOUVER A1 V6C 3E8
David D. Meek	officer: Chief Commercial Officer	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906